炎症性肠病新型治疗方法的研究进展

doi:10.12114/j.issn.1007-9572.2022.0720

摘要/Abstract

摘要： 炎症性肠病（IBD）是一组非特异性的慢性复发性肠道炎症性疾病，包括溃疡性结肠炎和克罗恩病。IBD的病因和发病机制仍未被完全阐明，目前也尚无治愈方法。随着研究不断深入，肿瘤坏死因子α、白介素、整合素受体、Janus激酶（JAK）/STAT通路和肠道菌群等靶点在IBD的病理生理学过程中发挥的作用被逐渐揭示，并随之涌现出多种新型的治疗方法，如生物制剂及小分子药物、干细胞移植、粪菌移植、白细胞吸附等。虽然不少新型治疗方法仍在研究阶段，但已初步展现出良好的疗效和安全性，未来或许可以弥补既往治疗方案的不足，为IBD患者的个体化治疗提供更多的选择。本文就新型IBD治疗方法的最新研究进展进行阐述。

关键词: 炎症性肠病, 克罗恩病, 溃疡性结肠炎, 治疗, 综述

Abstract:

Inflammatory bowel disease (IBD) is a chronic non-specific intestinal inflammatory disease featured by repetitive episodes of gastrointestinal inflammation, including ulcerative colitis and Crohn's disease. The etiology and pathogenesis of IBD have not been fully identified, and there is still no cure currently. Nevertheless, new treatments have been developed recently, such as biological agents and small-molecule drugs, stem cell transplantation, fecal bacteria transplantation, and monocyte adsorption apheresis, along with the roles of TNF-α, interleukin, integrin receptors, JAK/STAT pathway and intestinal flora in the pathophysiology of IBD gradually revealed by increasingly deepening research on IBD. Although many new treatments are still being researched, they have been proven effective and safe, which might make up for the shortcomings of previous therapies, and may be alternative choices for individualized treatment of IBD in the future. This article reviews the recent developments in novel treatments for IBD.

Key words: Inflammatory bowel disease, Crohn's disease, Ulcerative colitis, Therapy, Review

陈晓芬,陈钰涵,马娟. 炎症性肠病新型治疗方法的研究进展[J]. 中国全科医学, 2023, 26(27): 3349-3354. DOI: 10.12114/j.issn.1007-9572.2022.0720.
CHEN Xiaofen,CHEN Yuhan,MA Juan. Recent Strides in Novel Treatments for Inflammatory Bowel Disease[J]. Chinese General Practice, 2023, 26(27): 3349-3354. DOI: 10.12114/j.issn.1007-9572.2022.0720.

参考文献 39

[1]	CHEN C J, HU H, LIAO W T. Pathophysiology of inflammatory bowel diseases[J]. N Engl J Med，2021，384(14):1376-1377. DOI：10.1056/nejmc2101562.
[2]	FEUERSTEIN J D, ISAACS K L, SCHNEIDER Y, et al. AGA clinical practice guidelines on the management of moderate to severe ulcerative colitis[J]. Gastroenterology，2020，158(5):1450-1461. DOI：10.1053/j.gastro.2020.01.006.
[3]	LAMB C A, KENNEDY N A, RAINE T, et al. British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults[J]. Gut，2019，68(Suppl 3):s1-106. DOI：10.1136/gutjnl-2019-318484.
[4]	LAREDO V, GARGALLO-PUYUELO C J, GOMOLLÓN F. How to choose the biologic therapy in a bio-naïve patient with inflammatory bowel disease[J]. J Clin Med，2022，11(3):829. DOI：10.3390/jcm11030829.
[5]	OOI C J, HILMI I, BANERJEE R, et al. Best practices on immunomodulators and biologic agents for ulcerative colitis and Crohn's disease in Asia[J]. Intest Res，2019，17(3):285-310. DOI：10.5217/ir.2019.00026.
[6]	D'HAENS G R, VAN DEVENTER S. 25 years of anti-TNF treatment for inflammatory bowel disease：lessons from the past and a look to the future[J]. Gut，2021，70(7):1396-1405. DOI：10.1136/gutjnl-2019-320022.
[7]	MOSCHEN A R, TILG H, RAINE T. IL-12，IL-23 and IL-17 in IBD：immunobiology and therapeutic targeting[J]. Nat Rev Gastroenterol Hepatol，2019，16(3):185-196. DOI：10.1038/s41575-018-0084-8.
[8]	HONAP S, MEADE S, IBRAHEIM H, et al. Effectiveness and safety of ustekinumab in inflammatory bowel disease：a systematic review and meta-analysis[J]. Dig Dis Sci，2022，67(3):1018-1035. DOI：10.1007/s10620-021-06932-4.
[9]	HANAUER S B, SANDBORN W J, FEAGAN B G, et al. IM-UNITI：three-year efficacy，safety，and immunogenicity of ustekinumab treatment of Crohn's disease[J]. J Crohns Colitis，2020，14(1):23-32. DOI：10.1093/ecco-jcc/jjz110.
[10]	YANG H S, LI B Y, GUO Q, et al. Systematic review with meta-analysis：loss of response and requirement of ustekinumab dose escalation in inflammatory bowel diseases[J]. Aliment Pharmacol Ther，2022，55(7):764-777. DOI：10.1111/apt.16802.
[11]	FEAGAN B G, SANDBORN W J, D'HAENS G, et al. Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn's disease：a randomised，double-blind，placebo-controlled phase 2 study[J]. Lancet，2017，389(10080):1699-1709. DOI：10.1016/S0140-6736(17)30570-6.
[12]	SANDS B E, CHEN J J, FEAGAN B G, et al. Efficacy and safety of MEDI2070，an antibody against interleukin 23，in patients with moderate to severe Crohn's disease：a phase 2a study[J]. Gastroenterology，2017，153(1):77-86.e6. DOI：10.1053/j.gastro.2017.03.049.
[13]	SANDBORN W J, FERRANTE M, BHANDARI B R, et al. Efficacy and safety of mirikizumab in a randomized phase 2 study of patients with ulcerative colitis[J]. Gastroenterology，2020，158(3):537-549.e10. DOI：10.1053/j.gastro.2019.08.043.
[14]	SANDS B E, PEYRIN-BIROULET L, KIERKUS J, et al. Efficacy and safety of mirikizumab in a randomized phase 2 study of patients with Crohn's disease[J]. Gastroenterology，2022，162(2):495-508. DOI：10.1053/j.gastro.2021.10.050.
[15]	PARK S C, JEEN Y T. Anti-integrin therapy for inflammatory bowel disease[J]. World J Gastroenterol，2018，24(17):1868-1880. DOI：10.3748/wjg.v24.i17.1868.
[16]	BELLAGUARDA E, KEYASHIAN K, PEKOW J, et al. Prevalence of antibodies against JC virus in patients with refractory Crohn's disease and effects of natalizumab therapy[J]. Clin Gastroenterol Hepatol，2015，13(11):1919-1925. DOI：10.1016/j.cgh.2015.05.022.
[17]	CARD T, XU J, LIANG H F, et al. What is the risk of progressive multifocal leukoencephalopathy in patients with ulcerative colitis or Crohn's disease treated with vedolizumab? [J]. Inflamm Bowel Dis，2018，24(5):953-959. DOI：10.1093/ibd/izx097.
[18]	NAKASE H, UCHINO M, SHINZAKI S, et al. Evidence-based clinical practice guidelines for inflammatory bowel disease 2020[J]. J Gastroenterol，2021，56(6):489-526. DOI：10.1007/s00535-021-01784-1.
[19]	GUBATAN J, KEYASHIAN K, RUBIN S J S, et al. Anti-integrins for the treatment of inflammatory bowel disease：current evidence and perspectives[J]. Clin Exp Gastroenterol，2021，14:333-342. DOI：10.2147/CEG.S293272.
[20]	SALAS A, HERNANDEZ-ROCHA C, DUIJVESTEIN M, et al. JAK-STAT pathway targeting for the treatment of inflammatory bowel disease[J]. Nat Rev Gastroenterol Hepatol，2020，17(6):323-337. DOI：10.1038/s41575-020-0273-0.
[21]	SANDBORN W J, SU C, SANDS B E, et al. Tofacitinib as induction and maintenance therapy for ulcerative colitis[J]. N Engl J Med，2017，376(18):1723-1736. DOI：10.1056/NEJMoa1606910.
[22]	SANDBORN W J, GHOSH S, PANES J, et al. A phase 2 study of tofacitinib，an oral Janus kinase inhibitor，in patients with Crohn's disease[J]. Clin Gastroenterol Hepatol，2014，12(9):1485-1493.e2. DOI：10.1016/j.cgh.2014.01.029.
[23]	SANDBORN W J, PANÉS J, D'HAENS G R, et al. Safety of tofacitinib for treatment of ulcerative colitis，based on 4.4 years of data from global clinical trials[J]. Clin Gastroenterol Hepatol，2019，17(8):1541-1550. DOI：10.1016/j.cgh.2018.11.035.
[24]	PEYRIN-BIROULET L, CHRISTOPHER R, BEHAN D, et al. Modulation of sphingosine-1-phosphate in inflammatory bowel disease[J]. Autoimmun Rev，2017，16(5):495-503. DOI：10.1016/j.autrev.2017.03.007.
[25]	SANDBORN W J, FEAGAN B G, D'HAENS G R, et al. Ozanimod as induction and maintenance therapy for ulcerative colitis[J]. N Engl J Med，2021，385(14):1280-1291. DOI：10.1056/NEJMoa2033617.
[26]	SANDBORN W J, PEYRIN-BIROULET L, ZHANG J K, et al. Efficacy and safety of etrasimod in a phase 2 randomized trial of patients with ulcerative colitis[J]. Gastroenterology，2020，158(3):550-561. DOI：10.1053/j.gastro.2019.10.035.
[27]	PÉREZ-JELDRES T, ALVAREZ-LOBOS M, RIVERA-NIEVES J. Targeting sphingosine-1-phosphate signaling in immune-mediated diseases：beyond multiple sclerosis[J]. Drugs，2021，81(9):985-1002. DOI：10.1007/s40265-021-01528-8.
[28]	BEN GHEZALA I, CHARKAOUI M, MICHIELS C, et al. Small molecule drugs in inflammatory bowel diseases[J]. Pharmaceuticals （Basel），2021，14(7):637. DOI：10.3390/ph14070637.
[29]	FEAGAN B G, SANDS B E, ROSSITER G, et al. Effects of mongersen （GED-0301） on endoscopic and clinical outcomes in patients with active Crohn's disease[J]. Gastroenterology，2018，154(1):61-64.e6. DOI：10.1053/j.gastro.2017.08.035.
[30]	SANDS B E, FEAGAN B G, SANDBORN W J, et al. Mongersen （GED-0301） for active Crohn's disease：results of a phase 3 study[J]. Am J Gastroenterol，2020，115(5):738-745. DOI：10.14309/ajg.0000000000000493.
[31]	DANESE S, NEURATH M F, KOPON A, et al. Effects of apremilast，an oral inhibitor of phosphodiesterase 4，in a randomized trial of patients with active ulcerative colitis[J]. Clin Gastroenterol Hepatol，2020，18(11):2526-2534.e9. DOI：10.1016/j.cgh.2019.12.032.
[32]	TAN P F, LI X G, SHEN J, et al. Fecal microbiota transplantation for the treatment of inflammatory bowel disease：an update[J]. Front Pharmacol，2020，11:574533. DOI：10.3389/fphar.2020.574533.
[33]	STOJEK M, JABONSKA A, ADRYCH K. The role of fecal microbiota transplantation in the treatment of inflammatory bowel disease[J]. J Clin Med，2021，10(18):4055. DOI：10.3390/jcm10184055.
[34]	BRIERLEY C K, CASTILLA-LLORENTE C, LABOPIN M, et al. Autologous haematopoietic stem cell transplantation for Crohn's disease：a retrospective survey of long-term outcomes from the European society for blood and marrow transplantation[J]. J Crohns Colitis，2018，12(9):1097-1103. DOI：10.1093/ecco-jcc/jjy069.
[35]	RUIZ M A, KAISER R L Jr, DE QUADROS L G, et al. Low toxicity and favorable clinical and quality of life impact after non-myeloablative autologous hematopoietic stem cell transplant in Crohn's disease[J]. BMC Res Notes，2017，10(1):495. DOI：10.1186/s13104-017-2824-1.
[36]	ZHANG J, LV S M, LIU X J, et al. Umbilical cord mesenchymal stem cell treatment for Crohn's disease：a randomized controlled clinical trial[J]. Gut Liver，2018，12(1):73-78. DOI：10.5009/gnl17035.
[37]	CAO Y T, SU Q, ZHANG B J, et al. Efficacy of stem cells therapy for Crohn's fistula：a meta-analysis and systematic review[J]. Stem Cell Res Ther，2021，12(1):32. DOI：10.1186/s13287-020-02095-7.
[38]	YANG S P, LIANG X N, SONG J, et al. A novel therapeutic approach for inflammatory bowel disease by exosomes derived from human umbilical cord mesenchymal stem cells to repair intestinal barrier via TSG-6[J]. Stem Cell Res Ther，2021，12(1):315. DOI：10.1186/s13287-021-02404-8.
[39]	DOMÈNECH E, GRÍFOLS J R, AKBAR A, et al. Use of granulocyte/monocytapheresis in ulcerative colitis：a practical review from a European perspective[J]. World J Gastroenterol，2021，27(10):908-918. DOI：10.3748/wjg.v27.i10.908.